Elevated IgM antibodies targeting oncofetal antigens in melanoma patients may contribute to improved survival by enhancing immune recognition of tumor-associated antigens, activating complement-mediated cytotoxicity, and strengthening immune surveillance (84). This evidence concerns the gene CD40LG and melanoma.